Alliance Pharma plc announced that the second half of 2022 has got off to an encouraging start with trading in-line with expectations. The company anticipates strong sales growth in H2 across many of major brands, including Kelo-cote and Nizoral, continue to work closely to integrate new distribution partners and launch new products to grow market share. The company Fiscal Year 22 expectation includes certain large distributor orders in Fourth Quarter to meet increased demand, the timing of which is dependent on the rate of recovery in those markets.

The company remain committed to ensuring that consumers can access brands in the event of potential volatility in supply chains in the future.